Plenary Session:
281. Closing Plenary: From Science Fiction to Clinical Trial: The Use of Phage to Treat Antibiotic Resistant Infections
Sunday, October 7, 2018: 9:15 AM-10:45 AM
Room: W 2005-2024

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • describe the rationale, opportunities and challenges to the use of bacteriophages for the treatment of bacterial infections
  • discuss how phage lysins work as therapeutic agents against antibiotic resistant bacteria and their effectiveness

Target Audience: Academicians, Clinicians, Epidemiologists, Fellows, Healthcare workers, HIV clinicians, HIV specialists, Hospital administrators, Hospital epidemiologists, Infection preventionists, Infectious diseases pediatricians, Infectious diseases physicians, Investigators, Lab personnel, Medical students and residents, Members-in-training, Microbiologists, Nurses, Pharmacists, Public health practitioners, Researchers, Scientists, Vaccinologists

Tracks: Transplant ID, Trainee, Pediatric ID, Investigative ID, HIV-STD-TB, Global ID, Epidemiology and Infection Control, Adult ID


Moderators:  Roberta DeBiasi, MD, MS, FIDSA, FPIDS, Childrens National Health System/GWU School of Medicine and Cesar Arias, MD, PhD, FIDSA, University of Texas McGovern Medical School

CME Credits: Maximum of 1.50 hours of AMA PRA Category 1 Credit™

ACPE Credits: ACPE 1.5 knowledge-based contact hours of pharmacy CE

ACPE Number: 0221-9999-18-316-L01-P

Disclosures:

R. DeBiasi, Adaptive Phage Therapeutics: Collaborator and Investigator , Contract to cover costs associated with providing Ecoli and Klebsiella isolates for phage construction .

C. Arias, Merck & Co., Inc.: Grant Investigator , Research support . MeMed: Grant Investigator , Research support . Allergan: Grant Investigator , Research support .

See more of: Plenary Session
<< Previous Session | Next Session >>

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.